cerebral small vessel disease
Conditions
Interventions
high level HCY CSVD group:Folic acid tablet intervention
normal level HCY CSVD group:According to the condition, cooperate with routine antihypertensive, hypoglycemic and lipid-lowering drugs.
normal control group:According to the condition, cooperate with routine antihypertensive, hypoglycemic and lipid-lowering drugs.
Sponsors
Department of Neurology, the First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: Cerebral small vessel disease group: (1) aged 50–80 years, right-handed; (2) accompanied by at least one vascular risk factor (such as hypertension, diabetes, hyperlipidemia, and so on); (3) objective evidence of cognitive impairment in one or more domains; (4) met at least one imaging criteria: number of lacunar infarction =1; 3 scores for periventricular white matter hyperintensities or 2-3 scores for deep white matter hyperintensities, according to Fazekas rating scales; number of cerebral microbleeds =1 or moderate to severe dilated perivascular space (>10); (5) completed the cognitive evaluation and magnetic resonance imaging scanning involved in the study; (6) provided written informed consent by all participants or their relatives; (7) did not take vitamin D or any other drugs that may affect cognitive function 1 month before the experiment. Healthy controls: At the same time, healthy controls with matched characteristics of age, sex, and education were enrolled, who did not take folic acid or any other drugs that may affect cognitive function 1 month before the experiment.
Exclusion criteria
Exclusion criteria: (1) history of brain tumor, traumatic injury, or intracranial operation; (2) cerebral hemorrhage, large area cerebral infarction, or cerebrovascular stenosis; (3) history of aging-related diseases that cause cognitive impairment such as Parkinson's disease, Alzheimer's disease, or Lewy body dementia; (4) severe visuospatial deficits, hearing impairments, or language disorders; (5) major neurological or psychiatric illness or drug/alcohol use disorder; (6) liver, kidney, heart, and lung dysfunction or systemic malignant tumors; and (7) contraindications of magnetic resonance imaging scanning, such as in-vivo dentures, metallic stents or pacemakers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neuropsychological assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| multimodal magnetic resonance imaging metrics;HCY(homocysteine);folic acid;Vitamin B12; | — |
Countries
China
Contacts
Public ContactZhongwu Sun
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed